{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T04:24:37Z","timestamp":1794198277631,"version":"4.8.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007052","name":"Universit\u00e0 degli Studi di Verona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cigarette smoke is a significant risk factor for cardiovascular diseases (CVD). Among pharmacotherapy for smoking cessation, the plant alkaloid cytisine (CYT) -a nicotinic receptors partial agonist- has been shown to have a safe profile, with a minimal risk for drug interactions. Since previous studies have excluded CVD patients, there are few existing data examining CYT safety in this critical population. An observational prospective study was conducted in the Verona University Hospital (AOUI), Italy, to assess the safety and efficacy of CYT for smoking cessation. Thirty-six hospitalised participants from the Cardiology Department received oral CYT 1.5\u00a0mg for 25\u00a0days, according to the West Dosing Schedule (6 capsules for the first 3\u00a0days, gradually decreased up to 2 capsules on the last 6\u00a0days), in combination with supportive care. The primary endpoint was CYT safety, with 11 mild-moderate Adverse Drug Reactions (ADRs) reported by 9 (25%) participants. Initial insomnia (11%), nausea (6%), sleep disorders (6%), headache (3%), gastritis (3%), and diarrhoea (3%) were the most frequent symptoms. No serious or unexpected ADRs were identified, with no increase in cardiovascular events. Efficacy was assessed as self-reported 7-day point prevalence abstinence (PPA) at 3, 6 and 12\u00a0months post-quit. At the first follow-up, abstinence was also biochemically verified by exhaled carbon monoxide (CO) measurement, which was confirmed for 36% of participants. Considering lost to follow-up as relapsed patients, the PPA was 50%, 47% and 36% at 1st, 2nd and 3rd follow-up, respectively. These results may suggest that CYT has a well-established safety profile in hospitalised CVD patients, but further investigation is needed.<\/jats:p>","DOI":"10.1007\/s11739-025-03888-5","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T13:36:16Z","timestamp":1739367376000},"page":"817-828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cytisine for smoking cessation in hospitalised smokers with cardiovascular diseases: an observational study"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1664-4478","authenticated-orcid":false,"given":"Erika","family":"Tedesco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Ceccato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Torazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Losso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bottardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Casari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Melchiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Secchettin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Arzenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Lugoboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Chiamulera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"3888_CR1","doi-asserted-by":"publisher","first-page":"967047","DOI":"10.3389\/fpubh.2023.967047","volume":"11","author":"MA Mallah","year":"2023","unstructured":"Mallah MA et al (2023) Cigarette smoking and air pollution exposure and their effects on cardiovascular diseases. Front Public Health 11:967047","journal-title":"Front Public Health"},{"key":"3888_CR2","unstructured":"\u201cCardiovascular Diseases - The Health Consequences of Smoking\u201450 Years of Progress - NCBI Bookshelf.\u201d Accessed: May 06, 2024. [Online]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK294323\/"},{"issue":"12","key":"3888_CR3","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/J.JACC.2015.07.037","volume":"66","author":"PB Morris","year":"2015","unstructured":"Morris PB et al (2015) Cardiovascular effects of exposure to cigarette smoke and electronic cigarettes: clinical perspectives from the prevention of cardiovascular disease section leadership council and early career councils of the american college of cardiology. J Am Coll Cardiol 66(12):1378\u20131391. https:\/\/doi.org\/10.1016\/J.JACC.2015.07.037","journal-title":"J Am Coll Cardiol"},{"key":"3888_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-019-1351-4","volume":"17","author":"E Banks","year":"2019","unstructured":"Banks E et al (2019) Tobacco smoking and risk of 36 cardiovascular disease subtypes: fatal and non-fatal outcomes in a large prospective Australian study. BMC Med 17:1\u201318","journal-title":"BMC Med"},{"issue":"9861","key":"3888_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0140-6736(12)61720-6","volume":"381","author":"K Pirie","year":"2013","unstructured":"Pirie K, Peto R, Reeves GK, Green J, Beral V (2013) The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet 381(9861):133. https:\/\/doi.org\/10.1016\/S0140-6736(12)61720-6","journal-title":"Lancet"},{"issue":"2","key":"3888_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/J.GHEART.2012.05.003","volume":"7","author":"S Salahuddin","year":"2012","unstructured":"Salahuddin S, Prabhakaran D, Roy A (2012) Pathophysiological mechanisms of tobacco-related CVD. Glob Heart 7(2):113\u2013120. https:\/\/doi.org\/10.1016\/J.GHEART.2012.05.003","journal-title":"Glob Heart"},{"key":"3888_CR7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.35966","author":"O Okorare","year":"2023","unstructured":"Okorare O et al (2023) \u201cSmoking cessation and benefits to cardiovascular health: a review of literature. Cureus. https:\/\/doi.org\/10.7759\/cureus.35966","journal-title":"Cureus"},{"issue":"10","key":"3888_CR8","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.jacc.2003.12.047","volume":"43","author":"JA Ambrose","year":"2004","unstructured":"Ambrose JA, Barua RS (2004) The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 43(10):1731\u20131737. https:\/\/doi.org\/10.1016\/j.jacc.2003.12.047","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"3888_CR9","doi-asserted-by":"publisher","first-page":"7570","DOI":"10.3390\/JCM12247570","volume":"12","author":"A Pataka","year":"2023","unstructured":"Pataka A et al (2023) Obstructive Sleep Apnea and Smoking Increase the Risk of Cardiovascular Disease: Smoking Cessation Pharmacotherapy. J Clin Med 12(24):7570. https:\/\/doi.org\/10.3390\/JCM12247570","journal-title":"J Clin Med"},{"issue":"1","key":"3888_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/J.1360-0443.2004.00540.X","volume":"99","author":"JR Hughes","year":"2004","unstructured":"Hughes JR, Keely J, Naud S (2004) Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction (Abingdon, England) 99(1):29\u201338. https:\/\/doi.org\/10.1111\/J.1360-0443.2004.00540.X","journal-title":"Addiction (Abingdon, England)"},{"key":"3888_CR11","unstructured":"\u201cCardiovascular Diseases - How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease - NCBI Bookshelf.\u201d Accessed: Jul 03 2024. [Online]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK53012\/"},{"issue":"13","key":"3888_CR12","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMOA1102035","volume":"365","author":"R West","year":"2011","unstructured":"West R et al (2011) Placebo-Controlled Trial of Cytisine for Smoking Cessation. N Engl J Med 365(13):1193\u20131200. https:\/\/doi.org\/10.1056\/NEJMOA1102035","journal-title":"N Engl J Med"},{"issue":"2","key":"3888_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/096228029800700206","volume":"7","author":"J Stapleton","year":"1998","unstructured":"Stapleton J (1998) Cigarette smoking prevalence, cessation and relapse. Stat Methods Med Res 7(2):187\u2013203. https:\/\/doi.org\/10.1177\/096228029800700206","journal-title":"Stat Methods Med Res"},{"key":"3888_CR14","unstructured":"National center for chronic disease prevention and health promotion (US) Office on smoking and health. The Health Consequences of smoking\u201450 Years of progress: a report of the Surgeon General. Atlanta (GA): Centers for disease control and prevention (US); (2014). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK179276\/"},{"issue":"1","key":"3888_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2049-6958-9-9","volume":"9","author":"EY Ucar","year":"2014","unstructured":"Ucar EY et al (2014) Effectiveness of pharmacologic therapies on smoking cessation success: three years results of a smoking cessation clinic. Multidiscip Respir Med 9(1):9. https:\/\/doi.org\/10.1186\/2049-6958-9-9","journal-title":"Multidiscip Respir Med"},{"issue":"20","key":"3888_CR16","doi-asserted-by":"publisher","first-page":"13358","DOI":"10.3390\/ijerph192013358","volume":"19","author":"P Phusahat","year":"2022","unstructured":"Phusahat P et al (2022) Efficacy and safety of cytisine in combination with a community pharmacists\u2019 counselling for smoking cessation in thailand: a randomized double-blinded placebo-controlled trial. Int J Environ Res Public Health 19(20):13358","journal-title":"Int J Environ Res Public Health"},{"issue":"11","key":"3888_CR17","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1111\/ADD.14721","volume":"114","author":"P Tutka","year":"2019","unstructured":"Tutka P, Vinnikov D, Courtney RJ, Benowitz NL (2019) Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. Addiction (Abingdon, England) 114(11):1951\u20131969. https:\/\/doi.org\/10.1111\/ADD.14721","journal-title":"Addiction (Abingdon, England)"},{"key":"3888_CR18","doi-asserted-by":"publisher","unstructured":"Cahill K, Stevens S, Perera R, Lancaster T (2013) Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013(5):CD009329. https:\/\/doi.org\/10.1002\/14651858.CD009329.pub2","DOI":"10.1002\/14651858.CD009329.pub2"},{"issue":"6","key":"3888_CR19","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/JAMA.2022.0395","volume":"327","author":"NA Rigotti","year":"2022","unstructured":"Rigotti NA, Kruse GR, Livingstone-Banks J, Hartmann-Boyce J (2022) Treatment of tobacco smoking: a review. JAMA 327(6):566\u2013577. https:\/\/doi.org\/10.1001\/JAMA.2022.0395","journal-title":"JAMA"},{"key":"3888_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006103.pub7","author":"K Cahill","year":"2016","unstructured":"Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T (2016) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD006103.pub7","journal-title":"Cochrane Database Syst Rev"},{"issue":"7923","key":"3888_CR21","first-page":"f5198","volume":"347","author":"JJ Prochaska","year":"2013","unstructured":"Prochaska JJ, Das S, Benowitz NL (2013) Cytisine, the world\u2019s oldest smoking cessation aid: Growing evidence for its use as an affordable treatment globally. BMJ (Online) 347(7923):f5198","journal-title":"BMJ (Online)"},{"issue":"25","key":"3888_CR22","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1056\/NEJMOA1407764","volume":"371","author":"N Walker","year":"2014","unstructured":"Walker N et al (2014) Cytisine versus Nicotine for Smoking Cessation. N Engl J Med 371(25):2353\u20132362. https:\/\/doi.org\/10.1056\/NEJMOA1407764","journal-title":"N Engl J Med"},{"key":"3888_CR23","unstructured":"Tutka P, Zato\u0144ski W (2006) Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacol Rep 58(6):777\u2013798"},{"issue":"11","key":"3888_CR24","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1136\/THORAXJNL-2012-203035","volume":"68","author":"P Hajek","year":"2013","unstructured":"Hajek P, McRobbie H, Myers K (2013) Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. Thorax 68(11):1037\u20131042. https:\/\/doi.org\/10.1136\/THORAXJNL-2012-203035","journal-title":"Thorax"},{"key":"3888_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF02344189","volume":"37","author":"M Kunze","year":"1992","unstructured":"Kunze M et al (1992) Therapy for smoking: consensus in German-speaking countries. Soz Pr\/iventivmed 37:223\u2013230","journal-title":"Soz Pr\/iventivmed"},{"key":"3888_CR26","unstructured":"Bennodorf S, Kempe G, Scharfenberg G, Wendekamm R, Winkelvoss E (1968) Ergebnisse der medikament\u00f6sen Raucherentw\u00f6hnung mit Cytisin (Tabex). I [Results of the smoking-habit breaking using cytisin (Tabex). I]. Dtsch Gesundheitsw 23(44):2092\u20132096. (German)"},{"key":"3888_CR27","unstructured":"Stoyanov SYM (1965) Treatment of nicotinism with the Bulgarian drug, Tabex. Chimpharm Sofia. Chimpharm 2:13"},{"key":"3888_CR28","unstructured":"Benndorf S, Scharfenberg G, Kempe G, Wendekamm R, Winkelvoss E (1970) Medikament\u00f6se Raucherentw\u00f6hnung mit Cytisin (Tabex). Ergebnisse der Halbjahresbefragung bei den vier Wochen nach Kurbeginn abstinenten ehemaligen Rauchern [Smoking withdrawal treatment with Cytisin (Tabex). Results of a semi-annual survey of former smokers after 4 weeks of therapy]. Dtsch Gesundheitsw 24(17):774\u2013776. (German)"},{"issue":"10","key":"3888_CR29","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/ntr\/ntab073","volume":"23","author":"M Nides","year":"2021","unstructured":"Nides M, Rigotti NA, Benowitz N, Clarke A, Jacobs C (2021) A multicenter, double-blind, randomized, placebo-controlled phase 2b trial of cytisinicline in adult smokers (the Orca-1 Trial). Nicotine Tob Res 23(10):1656\u20131663. https:\/\/doi.org\/10.1093\/ntr\/ntab073","journal-title":"Nicotine Tob Res"},{"issue":"11","key":"3888_CR30","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1111\/ADD.14721","volume":"114","author":"P Tutka","year":"2019","unstructured":"Tutka P, Vinnikov D, Courtney RJ, Benowitz NL (2019) Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. Addiction 114(11):1951\u20131969. https:\/\/doi.org\/10.1111\/ADD.14721","journal-title":"Addiction"},{"key":"3888_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105700","volume":"170","author":"C Gotti","year":"2021","unstructured":"Gotti C, Clementi F (2021) Cytisine and cytisine derivatives. More than smoking cessation aids. Pharmacol Res 170:105700. https:\/\/doi.org\/10.1016\/j.phrs.2021.105700","journal-title":"Pharmacol Res"},{"issue":"11","key":"3888_CR32","doi-asserted-by":"publisher","first-page":"111090","DOI":"10.1016\/j.isci.2024.111090","volume":"27","author":"G Cohen","year":"2024","unstructured":"Cohen G, Bellanca CM, Bernardini R, Rose JE, Polosa R (2024) Personalized and adaptive interventions for smoking cessation: Emerging trends and determinants of efficacy. iScience 27(11):111090","journal-title":"iScience"},{"issue":"8","key":"3888_CR33","doi-asserted-by":"publisher","first-page":"813","DOI":"10.33963\/KP.A2021.0025","volume":"79","author":"B Ramotowski","year":"2021","unstructured":"Ramotowski B, Budaj A (2021) Is cytisine contraindicated in smoking patients with coronary artery disease after percutaneous coronary intervention? Kardiol Pol 79(8):813\u2013819. https:\/\/doi.org\/10.33963\/KP.A2021.0025","journal-title":"Kardiol Pol"},{"key":"3888_CR34","doi-asserted-by":"publisher","first-page":"1350176","DOI":"10.3389\/fpubh.2024.1350176","volume":"12","author":"A Torazzi","year":"2024","unstructured":"Torazzi A et al (2024) Safety and efficacy of CyTisine for smoking cessation in a hOSPital context (CITOSP): study protocol for a prospective observational study. Front Public Health 12:1350176","journal-title":"Front Public Health"},{"key":"3888_CR35","unstructured":"E. Medicines Agency, \u201cGuideline on good pharmacovigilance practices (GVP) - Module VI \u2013 Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2),\u201d 2017, Accessed: Sep. 27, 2024. [Online]. www.ema.europa.eu"},{"key":"3888_CR36","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA et al (2019) The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 95:103208","journal-title":"J Biomed Inform"},{"issue":"2","key":"3888_CR37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/J.JBI.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377\u2013381. https:\/\/doi.org\/10.1016\/J.JBI.2008.08.010","journal-title":"J Biomed Inform"},{"issue":"11","key":"3888_CR38","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.2105\/AJPH.77.11.1435","volume":"77","author":"MJ Jarvis","year":"1987","unstructured":"Jarvis MJ, Tunstall-Pedoe H, Feyerabend C, Vesey C, Saloojee Y (1987) Comparison of tests used to distinguish smokers from nonsmokers. Am J Public Health 77(11):1435\u20131438. https:\/\/doi.org\/10.2105\/AJPH.77.11.1435","journal-title":"Am J Public Health"},{"issue":"9","key":"3888_CR39","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/j.1360-0443.1991.tb01879.x","volume":"86","author":"TF Heatherton","year":"1991","unstructured":"Heatherton TF, Kozlowski LT, Frecker RC, FAGERSTROM KO (1991) The Fagerstr\u00f6m Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86(9):1119\u20131127","journal-title":"Br J Addict"},{"issue":"6","key":"3888_CR40","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/TC.2006.016097","volume":"15","author":"W Zatonski","year":"2006","unstructured":"Zatonski W, Cedzynska M, Tutka P, West R (2006) An uncontrolled trial of cytisine (Tabex) for smoking cessation. Tob Control 15(6):481. https:\/\/doi.org\/10.1136\/TC.2006.016097","journal-title":"Tob Control"},{"issue":"11","key":"3888_CR41","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/J.JCLINEPI.2015.04.014","volume":"68","author":"W Viechtbauer","year":"2015","unstructured":"Viechtbauer W et al (2015) A simple formula for the calculation of sample size in pilot studies. J Clin Epidemiol 68(11):1375\u20131379. https:\/\/doi.org\/10.1016\/J.JCLINEPI.2015.04.014","journal-title":"J Clin Epidemiol"},{"key":"3888_CR42","doi-asserted-by":"publisher","unstructured":"Fiore MC, Goplerud E, Schroeder SA (2012) The joint commission\u2019s new tobacco cessation measures\u2014Will Hospitals do the right thing? NEJM 366(13):1172\u20131174. https:\/\/doi.org\/10.1056\/NEJMp1115176","DOI":"10.1056\/NEJMp1115176"},{"key":"3888_CR43","unstructured":"\u201cFDA Drug Safety Communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease | FDA.\u201d Accessed: Jul. 24, 2024. [Online]. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-chantix-varenicline-may-increase-risk-certain-cardiovascular-adverse"},{"issue":"5","key":"3888_CR44","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1001\/JAMAINTERNMED.2018.0397","volume":"178","author":"NL Benowitz","year":"2018","unstructured":"Benowitz NL et al (2018) Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Intern Med 178(5):622\u2013631. https:\/\/doi.org\/10.1001\/JAMAINTERNMED.2018.0397","journal-title":"JAMA Intern Med"},{"issue":"10","key":"3888_CR45","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0195-668X(03)00003-4","volume":"24","author":"S Tonstad","year":"2003","unstructured":"Tonstad S et al (2003) Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 24(10):946\u2013955. https:\/\/doi.org\/10.1016\/S0195-668X(03)00003-4","journal-title":"Eur Heart J"},{"issue":"2","key":"3888_CR46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1161\/CIRCULATIONAHA.109.869008","volume":"121","author":"NA Rigotti","year":"2010","unstructured":"Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S (2010) Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 121(2):221\u2013229. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.869008","journal-title":"Circulation"},{"issue":"1","key":"3888_CR47","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/JAMA.296.1.56","volume":"296","author":"DE Jorenby","year":"2006","unstructured":"Jorenby DE et al (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296(1):56\u201363. https:\/\/doi.org\/10.1001\/JAMA.296.1.56","journal-title":"JAMA"},{"issue":"2","key":"3888_CR48","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1161\/CIRCULATIONAHA.109.869008","volume":"121","author":"NA Rigotti","year":"2010","unstructured":"Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S (2010) Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 121(2):221\u2013229","journal-title":"Circulation"},{"issue":"1","key":"3888_CR49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.113.003961","volume":"129","author":"EJ Mills","year":"2014","unstructured":"Mills EJ, Thorlund K, Eapen S, Wu P, Prochaska JJ (2014) Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 129(1):28\u201341. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.003961","journal-title":"Circulation"},{"key":"3888_CR50","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002849","author":"LH Sterling","year":"2016","unstructured":"Sterling LH, Windle SB, Filion KB, Touma L, Eisenberg MJ (2016) Varenicline and adverse cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.115.002849","journal-title":"J Am Heart Assoc"},{"key":"3888_CR51","doi-asserted-by":"publisher","first-page":"110936","DOI":"10.1016\/j.drugalcdep.2023.110936","volume":"251","author":"S Ofori","year":"2023","unstructured":"Ofori S et al (2023) Cytisine for smoking cessation: a systematic review and meta-analysis. Drug Alcohol Depend 251:110936","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"3888_CR52","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/JAMA.2021.7621","volume":"326","author":"RJ Courtney","year":"2021","unstructured":"Courtney RJ et al (2021) Effect of Cytisine vs Varenicline on Smoking Cessation: a Randomized Clinical Trial. JAMA - J Am Med Association 326(1):56\u201364. https:\/\/doi.org\/10.1001\/JAMA.2021.7621","journal-title":"JAMA - J Am Med Association"},{"issue":"15","key":"3888_CR53","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/ARCHINTE.166.15.1553","volume":"166","author":"JF Etter","year":"2006","unstructured":"Etter JF (2006) Cytisine for smoking cessation a literature: Review and a meta-analysis. Arch Intern Med 166(15):1553\u20131559. https:\/\/doi.org\/10.1001\/ARCHINTE.166.15.1553","journal-title":"Arch Intern Med"},{"issue":"4","key":"3888_CR54","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/ADD.16399","volume":"119","author":"O De Santi","year":"2024","unstructured":"De Santi O, Orellana M, Di Niro CA, Greco V (2024) Evaluation of the effectiveness of cytisine for the treatment of smoking cessation: a systematic review and meta-analysis. Addiction 119(4):649\u2013663. https:\/\/doi.org\/10.1111\/ADD.16399","journal-title":"Addiction"},{"key":"3888_CR55","unstructured":"Agenzia Italiana del Farmaco. Defucitan (Citisina)\u2014Riassunto delle caratteristiche del prodotto. https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/organizzazione\/5201\/farmaci\/48493\/stampati\/RCP"},{"key":"3888_CR56","doi-asserted-by":"publisher","first-page":"115874","DOI":"10.1016\/j.psychres.2024.115874","volume":"335","author":"Y Song","year":"2024","unstructured":"Song Y, Park YA, Lee DH, Yee J, Gwak HS (2024) Sleep-related adverse events of smoking cessation drugs: A network meta-analysis of randomized controlled trials. Psychiatry Res 335:115874","journal-title":"Psychiatry Res"},{"issue":"8","key":"3888_CR57","doi-asserted-by":"publisher","first-page":"E2225129","DOI":"10.1001\/JAMANETWORKOPEN.2022.25129","volume":"5","author":"HA Tindle","year":"2022","unstructured":"Tindle HA et al (2022) Effectiveness of Varenicline and Cytisine for Alcohol Use Reduction among People with HIV and Substance Use: A Randomized Clinical Trial. JAMA Netw Open 5(8):E2225129. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2022.25129","journal-title":"JAMA Netw Open"},{"key":"3888_CR58","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/resp.14787","volume":"29","author":"S Rungruanghiranya","year":"2024","unstructured":"Rungruanghiranya S et al (2024) Efficacy and safety of cytisine versus nortriptyline for smoking cessation: A multicentre, randomized, double-blinded and placebo-controlled trial. Respirology 29:880\u2013887","journal-title":"Respirology"},{"issue":"2","key":"3888_CR59","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/JAMA.2023.10042","volume":"330","author":"NA Rigotti","year":"2023","unstructured":"Rigotti NA et al (2023) Cytisinicline for smoking cessation: a randomized clinical trial. JAMA 330(2):152\u2013160. https:\/\/doi.org\/10.1001\/JAMA.2023.10042","journal-title":"JAMA"},{"issue":"2","key":"3888_CR60","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1177\/03008916231216906","volume":"110","author":"P Pozzi","year":"2024","unstructured":"Pozzi P et al (2024) Cytisine as a smoking cessation aid: Preliminary observations with a modified therapeutic scheme in real life. Tumori 110(2):124\u2013131. https:\/\/doi.org\/10.1177\/03008916231216906","journal-title":"Tumori"},{"key":"3888_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18332\/tpc\/187556","volume":"10","author":"B Tinghino","year":"2024","unstructured":"Tinghino B et al (2024) Cytisine for smoking cessation: A 40-day treatment with an induction period. Tob Prev Cessat 10:1\u20137","journal-title":"Tob Prev Cessat"},{"issue":"10","key":"3888_CR62","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1111\/ADD.15489","volume":"116","author":"N Walker","year":"2021","unstructured":"Walker N et al (2021) Cytisine versus varenicline for smoking cessation in New Zealand indigenous M\u0101ori: a randomized controlled trial. Addiction 116(10):2847\u20132858. https:\/\/doi.org\/10.1111\/ADD.15489","journal-title":"Addiction"},{"key":"3888_CR63","unstructured":"Istituto Superiore della Sanit\u00e0 . Linea guida per il trattamento della dipendenza da tabacco e da nicotina. (2023)  https:\/\/www.pnrr.salute.gov.it\/imgs\/C_17_pubblicazioni_3324_allegato.pdf"},{"key":"3888_CR64","doi-asserted-by":"publisher","unstructured":"Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, Lindson N (2023) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2023(6):CD006103. https:\/\/doi.org\/10.1002\/14651858.CD006103.pub9","DOI":"10.1002\/14651858.CD006103.pub9"},{"key":"3888_CR65","unstructured":"Istituto Superiore della Sanit\u00e0. Materiali supplementari - Linea guida per il trattamento della dipendenza da tabacco e da nicotina. (2023). https:\/\/www.amedeolucente.it\/public\/Materiali%20supplementari%20LG%20Dipendenze%20Tabacco%20e%20Nicotina.pdf"},{"key":"3888_CR66","unstructured":"AIFA . CHAMPIX (varenicline)\u2014Lots to be recalled due to presence of impurity N-nitroso-varenicline above the Pfizer\nacceptable daily intake limit. (2021). https:\/\/www.aifa.gov.it\/documents\/20142\/1313724\/2021.07.15_NII_CHAMPIX_EN.pdf"}],"updated-by":[{"DOI":"10.1007\/s11739-025-04067-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000}}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-025-03888-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-025-03888-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-025-03888-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T04:52:35Z","timestamp":1757134355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-025-03888-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3888"],"URL":"https:\/\/doi.org\/10.1007\/s11739-025-03888-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11739-025-04067-2","asserted-by":"object"}]},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11739-025-04067-2","URL":"https:\/\/doi.org\/10.1007\/s11739-025-04067-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study protocol was approved by the Local Ethics Committee on September 23rd 2021 (reference protocol number 55360-3439CESC). This study was carried out in accordance with the principles expressed in the Declaration of Helsinki, and we ensured protection of patient privacy and anonymity.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from patients or their surrogates before enrollment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}